Recruiting studies: Recurrent Non Muscle Invasive Bladder Urothelial Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT06167356 Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive B
Phase 3 · 6 location(s) · Verity Pharmaceuticals Inc. · NCT05037279 A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Mi
Phase N/A · 1 location(s) · Peking University First Hospital · NCT06991868 Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthra
Phase 1 · 1 location(s) · First Affiliated Hospital of Chongqing Medical University · NCT06766266 Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
Phase 2 · 1 location(s) · Michael A. O'Donnell · NCT07322263 Prospective Sample Collection for Cancer of Bladder
Phase N/A · 1 location(s) · Universitaire Ziekenhuizen KU Leuven · NCT03973671 A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer
Phase 1 · 6 location(s) · University of Wisconsin, Madison · NCT05521698 Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy T
Phase 2 · 134 location(s) · National Cancer Institute (NCI) · NCT06770582

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.